Bronchiectasis-associated infections and outcomes in a large, geographically diverse electronic health record cohort in the United States

BMC Pulm Med. 2024 Apr 10;24(1):172. doi: 10.1186/s12890-024-02973-3.

Abstract

Background: Bronchiectasis is a pulmonary disease characterized by irreversible dilation of the bronchi and recurring respiratory infections. Few studies have described the microbiology and prevalence of infections in large patient populations outside of specialized tertiary care centers.

Methods: We used the Cerner HealthFacts Electronic Health Record database to characterize the nature, burden, and frequency of pulmonary infections among persons with bronchiectasis. Chronic infections were defined based on organism-specific guidelines.

Results: We identified 7,749 patients who met our incident bronchiectasis case definition. In this study population, the organisms with the highest rates of isolate prevalence were Pseudomonas aeruginosa with 937 (12%) individuals, Staphylococcus aureus with 502 (6%), Mycobacterium avium complex (MAC) with 336 (4%), and Aspergillus sp. with 288 (4%). Among persons with at least one isolate of each respective pathogen, 219 (23%) met criteria for chronic P. aeruginosa colonization, 74 (15%) met criteria for S. aureus chronic colonization, 101 (30%) met criteria for MAC chronic infection, and 50 (17%) met criteria for Aspergillus sp. chronic infection. Of 5,795 persons with at least two years of observation, 1,860 (32%) had a bronchiectasis exacerbation and 3,462 (60%) were hospitalized within two years of bronchiectasis diagnoses. Among patients with chronic respiratory infections, the two-year occurrence of exacerbations was 53% and for hospitalizations was 82%.

Conclusions: Patients with bronchiectasis experiencing chronic respiratory infections have high rates of hospitalization.

Keywords: Bronchiectasis; Epidemiology; Exacerbations; Hospitalization; Respiratory infections.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bronchiectasis* / complications
  • Bronchiectasis* / epidemiology
  • Electronic Health Records
  • Humans
  • Mycobacterium avium Complex
  • Persistent Infection
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas aeruginosa
  • Respiratory Tract Infections* / complications
  • Staphylococcus aureus
  • United States / epidemiology

Substances

  • Anti-Bacterial Agents